Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis

Brain metastasis is a common cause of mortality in cancer patients, yet potential therapeutic targets remain largely unknown. The type I insulin-like growth factor receptor (IGF-IR) is known to play a role in the progression of breast cancer and is currently being investigated in the clinical setting for various types of cancer. The present study demonstrates that IGF-IR is constitutively autophosphorylated in brain-seeking breast cancer sublines. Knockdown of IGF-IR results in a decrease of phospho-AKT and phospho-p70s6k, as well as decreased migration and invasion of MDA-MB-231Br brain-seeking cells. In addition, transient ablation of IGFBP3, which is overexpressed in brain-seeking cells, blocks IGF-IR activation. Using an in vivo experimental brain metastasis model, we show that IGF-IR knockdown brain-seeking cells have reduced potential to establish brain metastases. Finally, we demonstrate that the malignancy of brain-seeking cells is attenuated by pharmacological inhibition with picropodophyllin, an IGF-IR-specific tyrosine kinase inhibitor. Together, our data suggest that the IGF-IR is an important mediator of brain metastasis and its ablation delays the onset of brain metastases in our model system.

[1]  O. Larsson,et al.  Correction: The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway , 2022, Oncogene.

[2]  R. Baxter,et al.  IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments , 2013, Oncogene.

[3]  P. Tan,et al.  Insulin growth factor receptor‐1 expression and loss of PTEN protein predict early recurrence in triple‐negative breast cancer , 2012, Histopathology.

[4]  T. Yoneda,et al.  Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. , 2012, Cancer research.

[5]  E. Lerma,et al.  Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas , 2012, British Journal of Cancer.

[6]  I. Torres-Aleman,et al.  The many faces of insulin-like peptide signalling in the brain , 2012, Nature Reviews Neuroscience.

[7]  S. Lakhani,et al.  Molecular Aspects of Breast Cancer Metastasis to the Brain , 2011, Genetics research international.

[8]  R. Stephens,et al.  Response to "Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients." (Int J Radiat Oncol Biol Phys 2010:77:655-661). , 2011, International journal of radiation oncology, biology, physics.

[9]  R. Baxter,et al.  Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3 , 2011, Growth factors.

[10]  R. Jain,et al.  The biology of brain metastases—translation to new therapies , 2011, Nature Reviews Clinical Oncology.

[11]  Zoë Davison,et al.  Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. , 2011, Neoplasia.

[12]  E. Petricoin,et al.  Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. , 2011, Journal of proteome research.

[13]  K. Camphausen,et al.  Brain metastases as preventive and therapeutic targets , 2011, Nature Reviews Cancer.

[14]  Adrian V. Lee,et al.  High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy , 2010, Clinical Cancer Research.

[15]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[16]  C. Abrams,et al.  All-atom structural models for complexes of insulin-like growth factors IGF1 and IGF2 with their cognate receptor. , 2010, Journal of molecular biology.

[17]  Kuk-Wha Lee,et al.  Nuclear export and mitochondrial and endoplasmic reticulum localization of IGF-binding protein 3 regulate its apoptotic properties. , 2010, Endocrine-related cancer.

[18]  R. Baxter,et al.  Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells , 2009, Growth factors.

[19]  P. Brown,et al.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.

[20]  D. Yee,et al.  The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival , 2009, Oncogene.

[21]  R. Baxter,et al.  Potentiation of Growth Factor Signaling by Insulin-like Growth Factor-binding Protein-3 in Breast Epithelial Cells Requires Sphingosine Kinase Activity* , 2009, The Journal of Biological Chemistry.

[22]  N. Sibson,et al.  The Vascular Basement Membrane as “Soil” in Brain Metastasis , 2009, PloS one.

[23]  H. Masoudi,et al.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. , 2008, Cancer research.

[24]  M. Pollak,et al.  The Type 1 Insulin-Like Growth Factor Receptor Pathway , 2008, Clinical Cancer Research.

[25]  M. Hung,et al.  Breast cancer brain metastases , 2007, Cancer and Metastasis Reviews.

[26]  O. Fodstad,et al.  Association of insulin-like growth factor binding protein-3 expression with melanoma progression , 2006, Molecular Cancer Therapeutics.

[27]  O. Larsson,et al.  IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. , 2006, Blood.

[28]  O. Larsson,et al.  Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. , 2006, Blood.

[29]  R. Weil,et al.  Breast cancer metastasis to the central nervous system. , 2005, The American journal of pathology.

[30]  U. Sivaprasad,et al.  Stimulation of insulin-like growth factor (IGF) binding protein-3 synthesis by IGF-I and transforming growth factor-alpha is mediated by both phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways in mammary epithelial cells. , 2004, Endocrinology.

[31]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Yong Liao,et al.  Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients , 2004, Clinical Cancer Research.

[33]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[34]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[35]  R. Baxter,et al.  Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. , 2004, The Journal of clinical endocrinology and metabolism.

[36]  O. Larsson,et al.  Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth , 2004, Cancer Research.

[37]  Peter O. Krutzik,et al.  Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[38]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[39]  C. McCaig,et al.  Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin , 2002, Journal of Cell Science.

[40]  L. Graham,et al.  Role of insulin‐like growth factor binding protein‐3 in breast cancer cell growth , 2002, Microscopy research and technique.

[41]  D. Hanahan,et al.  Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. , 2002, Cancer cell.

[42]  D. Yee,et al.  Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines , 2001, Oncogene.

[43]  Paul J. Williams,et al.  A Bone‐Seeking Clone Exhibits Different Biological Properties from the MDA‐MB‐231 Parental Human Breast Cancer Cells and a Brain‐Seeking Clone In Vivo and In Vitro , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[45]  R. Baxter,et al.  Oncogenic ras Causes Resistance to the Growth Inhibitor Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) in Breast Cancer Cells* , 1999, The Journal of Biological Chemistry.

[46]  R. Baxter,et al.  Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. , 1999, The Journal of endocrinology.

[47]  R. Baxter,et al.  Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. , 1998, Biochemical and biophysical research communications.

[48]  J. Price,et al.  Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[49]  C. Conover,et al.  Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. , 1991, Endocrinology.

[50]  T. Yoshimine,et al.  Immunohistochemical study of metastatic brain tumors with astroprotein (GFAP), a glia-specific protein. Tissue architecture and the origin of blood vessels. , 1985, Journal of neurosurgery.

[51]  E. Lasfargues,et al.  Isolation of two human tumor epithelial cell lines from solid breast carcinomas. , 1978, Journal of the National Cancer Institute.

[52]  M. Buyse,et al.  Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. , 2012, The oncologist.

[53]  O. Larsson,et al.  Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. , 2010, Neuro-oncology.

[54]  C T Roberts,et al.  Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. , 1994, Molecular endocrinology.